A key focus for PTX is CAR-T. They announced a partnership, but have not been able to disclose anything yet. If you watch the interviews with the CEO, he hints that PTX is enabling pathways for CAR-T to target a diverse cancer set, where previously CAR-T is very limited. Very similar to the announcement you have provided.
This company is extremely interesting, they are on the bleeding edge of cancer treatments, a diversified portfolio, multiple pathways to blockbuster status. All very risky as is the nature of BIO's. I am looking forward to seeing where this company goes in the next 12 months.
PTX Price at posting:
5.6¢ Sentiment: Hold Disclosure: Held
